HBK Sorce Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

HBK Sorce Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-194	Closed	-$204K	–	598
2024 Q2	$204K	Buy	+194	New	+$188K	0.01%	520
2021 Q1	–	Sell	-801	Closed	-$387K	–	555
2020 Q4	$387K	Sell	801 -135	-14%	-$72.9K	0.02%	322
2020 Q3	$524K	Sell	936 -202	-18%	-$122K	0.04%	250
2020 Q2	$710K	Buy	+1,138	New	+$646K	0.05%	204
2017 Q4	–	Sell	-451	Closed	-$202K	–	393
2017 Q3	$202K	Sell	451 -1	-0.2%	-$476	0.03%	304
2017 Q2	$222K	Buy	+452	New	+$198K	0.04%	277
2016 Q4	–	Sell	-511	Closed	-$205K	–	296
2016 Q3	$205K	Buy	+511	New	+$205K	0.04%	267

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HBK Sorce Advisory's REGN Position: Q3 2024 in Review

HBK Sorce Advisory sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 194 shares — an estimated $204K sold.

HBK Sorce Advisory first reported a position in REGN in Q3 2016 and held it in 7 quarters. The position peaked at $710K in Q2 2020. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

HBK Sorce Advisory reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
HBK Sorce Advisory sold 194 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $204K.
HBK Sorce Advisory first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 7 quarters.
HBK Sorce Advisory's Regeneron Pharmaceuticals position peaked at $710K in Q2 2020.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on HBK Sorce Advisory's 13F filing for Q3 2024, filed 12 Nov 2024.